Brought to you by 
Series B brings in €25mm for Pieris AG
24 Apr 2008
Executive Summary
New investors OrbiMed Advisors and Novo Nordisk Biotech Fund led Pieris AG's (developing Anticalins, a class of proteins used in the diagnosis and treatment of diseases) €25mm ($38mm) Series B venture round. All returning shareholders, including Global Life Science Ventures, Gilde Healthcare Partners, and Forbion Capital Partners also participated. A member of OrbiMed will take a seat on the company's board.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B brings in €25mm for Pieris AG
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice